Literature DB >> 3577482

Erythema chronicum migrans Afzelius in Sweden. A study on 231 patients.

E Asbrink, I Olsson, A Hovmark.   

Abstract

In order to describe the clinical manifestations of erythema chronicum migrans Afzelius (ECMA) in Sweden and to compare them with those in Lyme disease in the United States, 231 patients with ECMA were investigated. Although there are many similarities between the two disorders the findings also point to differences. The skin lesions were of longer duration (median 5-6 weeks) than those in Lyme disease but less often multiple (8%). General symptoms were found in about half of the patients with a short disease duration (less than or equal to 3 weeks), but were usually mild. Laboratory abnormalities were noted in only a minority of the cases. At the time of diagnosis none of the patients had spirochete-induced arthritis, but in three of them cardiac involvement was suspected. Among 16 untreated patients meningitis later developed in two patients and arthritis in one. Diagnostic procedures such as serologic testing and cultivation of spirochetes are discussed.

Entities:  

Mesh:

Year:  1986        PMID: 3577482     DOI: 10.1016/s0176-6724(86)80126-2

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN: 0176-6724


  14 in total

Review 1.  Antibiotic treatment of Lyme borreliosis: what is the evidence?

Authors:  R Dinser; M C Jendro; S Schnarr; H Zeidler
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

2.  Increased incidence of Lyme borreliosis in southern Sweden following mild winters and during warm, humid summers.

Authors:  L Bennet; A Halling; J Berglund
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

3.  Epidemiological study of a cohort of adult patients with Erythema migrans registered in Slovenia in 1993.

Authors:  F Strle; V Maraspin; S Furlan-Lotric; J Cimperman
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

4.  One year follow-up study to assess the prevalence and incidence of Lyme borreliosis among Dutch forestry workers.

Authors:  H Kuiper; A P van Dam; A W Moll van Charante; N P Nauta; J Dankert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

5.  2nd European Symposium on Lyme Borreliosis. A NATO advanced research workshop. United Kingdom, 19-20 May 1993. Abstracts.

Authors: 
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

6.  Isolation of Borrelia burgdorferi from biopsy specimens taken from healthy-looking skin of patients with Lyme borreliosis.

Authors:  H Kuiper; A P van Dam; L Spanjaard; B M de Jongh; A Widjojokusumo; T C Ramselaar; I Cairo; K Vos; J Dankert
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

7.  Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.

Authors:  V Preac Mursic; W Marget; U Busch; D Pleterski Rigler; S Hagl
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

8.  Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans.

Authors:  F Strle; V Maraspin; S Lotric-Furlan; E Ruzić-Sabljić; J Cimperman
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

9.  Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis.

Authors:  R Muellegger; N Zoechling; E M Schluepen; H P Soyer; S Hoedl; M Volkenandt
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

10.  The 93-kilodalton protein of Borrelia burgdorferi: an immunodominant protoplasmic cylinder antigen.

Authors:  B J Luft; S Mudri; W Jiang; R J Dattwyler; P D Gorevic; T Fischer; P Munoz; J J Dunn; W H Schubach
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.